2cureX publishes the annual report for the fiscal year 2021

May 3 | 2022

Copenhagen — May 3, 2022 — The Board of Directors and the CEO of 2cureX AB (“2cureX”) hereby publish the annual report for the fiscal year 2021. The annual report and associated audit report are available as an attached file and on the company’s website (www.2curex.com).

On May 24th, 2022 the Annual report will be presented for approval at the Annual General Meeting, as announced on the 21st April 2022, in the notice to attend the Annual General Meeting of 2cureX AB.

The Annual report will be presented at a live webcast, on May 24th 2022 at 15:00 CET. Further access details will be accessible on www.2curex.com.

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The portfolio of IndiTreat® tests is aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® mCRC Start for first line of therapy, IndiTreat® mCRC Extend and IndiTreat® mCRC Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
 
Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se

This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-05-03 20:45 CEST.

Attachments

2curex Annual Report UK 2021 FINAL

Previous Next